Study to Evaluate the Safety & Performance of the Xpert(TM) Stent in Treating Below-the-knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic CLI.

NCT ID: NCT00515346

Last Updated: 2013-12-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-07-31
• Study Completion Date: 2011-09-30

Brief Summary

The purpose of this study is to evaluate the safety and performance of the Xpert(TM) self-expanding stent in infrapopliteal lesions as part of an overall treatment strategy in patients undergoing percutaneous intervention for the treatment of documented chronic critical limb ischemia (CLI).

Detailed Description

Peripheral arterial disease (PAD) of the lower extremities affects roughly 25 million Americans annually. The diabetic population is particularly prone to the most severe clinical problems associated with PAD and the amputation rate amongst such patients is elevated five-fold. It has been shown that patients who undergo amputation for PAD/CLI have a much higher mortality rate in the months that follow.

Despite medical advances in the fields of pharmacology and wound care, the vast majority of patients who present with CLI will ultimately require amputation in the absence of improved blood flow. Recently, much attention has been directed towards less invasive endovascular solutions for treating patients with CLI. This study will evaluate approximately 140 subjects with Rutherford Class IV-VI PAD in a multi-center study in order to accurately estimate limb salvage rates for this treatment.

Conditions

Chronic Critical Limb Ischemia; Peripheral Vascular Diseases

Keywords

CLI; Critical Limb Ischemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient has documented wound care greater than or equal to 2 weeks prior to enrollment
• Subject understands the duration of the study and its follow up visit requirements
• Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation
• Subject has documented chronic critical limb ischemia in the target limb for two weeks with Rutherford Category 4, 5 or 6
• Subject must have one of 5 approved non-invasive test results of the target limb within two weeks of enrollment.

Exclusion Criteria

• Life expectancy of less than 12 months
• Cerebrovascular accident (CVA) or myocardial infarction (MI) within 3 months prior to enrollment
• Inability to walk (with assistance is accepted)
• Previous bypass surgery to target limb less than 30 days prior to study procedure
• Acute thrombus at the lesion site(s)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prairie Education and Research Cooperative

INDUSTRY

Sponsor Role: collaborator

VIVA Physicians

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

James D. Joye, DO

Role: PRINCIPAL_INVESTIGATOR

VIVA Physicians Inc.

Locations

VIVA Physicians Inc.

San Jose, California, United States

Countries

United States

Related Links

http://www.prairieresearch.com/trial_XCELL_P.html

Click here for more information about this study

Other Identifiers

G060029

Identifier Type: -

Identifier Source: org_study_id